Clinical TrialJul 27, 2026, 07:06 AM
Camp4 Secures Australian Clearance for CMP-002 Trial; Triggers $50M Funding
AI Summary
Camp4 Therapeutics Corporation announced it has received clearance from Australia’s Therapeutic Goods Administration (TGA) and local Human Research Ethics Committee (HREC) to initiate a Phase 1/2 clinical trial for CMP-002. This investigational product candidate is designed to treat SYNGAP1-related disorder. This regulatory milestone satisfies conditions in a September 2025 Securities Purchase Agreement, making the company eligible to receive up to an additional $50.1 million in gross proceeds from a second closing, expected around August 3, 2026.
Key Highlights
- Received clearance from Australia's TGA and HREC to initiate Phase 1/2 clinical trial for CMP-002.
- CMP-002 is an investigational product for SYNGAP1-related disorder, a potential first-in-class therapeutic.
- Regulatory clearance satisfied the CTA Milestone and Price Threshold Waiver from September 2025 Purchase Agreement.
- Company is eligible to receive up to approximately $50.1 million in gross proceeds from the Second Closing.
- Second Closing is expected around August 3, 2026, for up to 32,721,172 shares of common stock or warrants.
- Participating investors include Coastlands Capital, Janus Henderson Investors, and Vivo Capital.
Price Impact
More from CAMP